This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).

In a report released today, Dale Lai from DBS maintained a Buy rating on Digital Core REIT (DCRU – Research Report), with a price target of ...

Canada Pension Plan Investment Board (CPP Investments) ended its third quarter on December 31, 2024, with net assets of $699.6 billion, compared to $675.1 billion ...

The organization is pushing forward with implementation of an ambitious community development agenda, with the help of community partners.

DBS analyst Dale Lai maintained a Buy rating on ESR-REIT (CGIUF – Research Report) today and set a price target of S$0.31. The company’s shares ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Anyone can develop an inflammation but in some people it may be silent Therefore getting proper tests can help confirm your ...

As a child, I'd cry out at night due to the pains in my knees, my hips, my elbows, and my wrists, and the pediatrician made note several times about an increased SED rate on my lab work (noting ...

Q4 pre-tax adjusted operating income was $1.4 billion, translating to $2.96 per share, with full-year 2024 adjusted operating income at $5.9 billion or $12.62 per share, a 6% increase from 2023. PGIM ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

As global markets navigate a complex landscape marked by fluctuating interest rates and geopolitical tensions, investors are keenly observing the implications of AI competition and tariff risks on ...

We profile four reliable REITs with high occupancies and positive rental reversion that you can consider for your buy ...